Company intelligence / Profile preview
Tenaya Therapeutics
South San Francisco, California, United Statestenayatherapeutics.gcs-web.com ↗
- Ownership
- Public · TNYA
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
TN-201 has been well tolerated at 3E13 vg/kg dose in Cohort 1 of MyPEAK-1 trial with evidence of transgene RNA expression and increasing MyBP-C protein levels over time. Cohort 2 dosing at 6E13 vg/kg is ongoing. TN-401 is in Phase 1b clinical trial (RIDGE-1) with initial data expected in second half of 2025[6][9].
- Therapeutic areas
- Cardiovascular
- Modalities
- Gene TherapyCellular RegenerationSmall Molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $143.4M
- Total revenue
- $1.1M
- Enterprise value
- $69.3M
Beyond the preview
Go deeper on Tenaya Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenaya Therapeutics.